Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 7,719 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level 2 Clear all
Completed Phase 1 Interventional Results available

Study To Evaluate The Effect Of Two Steady State Doses of PF 06882961 On Rosuvastatin And Midazolam Pharmacokinetics In Otherwise Healthy Adult Participants With Obesity

NCT04621227
View directory record Official record
Conditions
Obesity
Interventions
PF-06882961, Rosuvastatin, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

NCT00864227
View directory record Official record
Conditions
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
Interventions
Hematopoietic Umbilical Cord Blood Stem Cell Transplantation, GVHD prophylaxis
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
1 Year to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Duarte, California • Gainesville, Florida • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 22, 2026, 5:25 AM EDT
Not listed Phase 1 Interventional

Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy

NCT03217669
View directory record Official record
Conditions
Advanced Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
Interventions
Epacadostat, sirolimus
Drug
Lead sponsor
Chao Huang
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Fairway, Kansas • Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional

Tdcs And cogNitive traininG cOmbined for AUD (TANGO)

NCT05062369
View directory record Official record
Conditions
Alcohol Use Disorder, Addiction
Interventions
TaskFlow Transcranial Electrical Stimulation device, Executive Function Focused Cognitive Training
Device · Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

PUSH Plus Protein Pilot for Hip Fracture Patients

NCT03410823
View directory record Official record
Conditions
Hip Fracture
Interventions
PUSH, Protein, Nutrition
Behavioral · Dietary Supplement
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

BiliCam Clinical Validation Study

NCT03246503
View directory record Official record
Conditions
Newborn Jaundice
Interventions
BiliCam estimated bilirubin (BCB)
Device
Lead sponsor
BiliCam, LLC
Industry
Eligibility
0 Hours to 191 Hours
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 22, 2026, 5:25 AM EDT
Not listed Not applicable Interventional

Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration

NCT02379689
View directory record Official record
Conditions
Degenerative Disc Disease, Pain
Interventions
Injectable placental tissue extract called BioDGenesis (Active Product), Placebo
Drug
Lead sponsor
Semmes-Murphey Foundation
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Puyallup, Washington, Washington
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 3 Interventional

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

NCT06112990
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
creatine monohydrate, Placebo, Home-based, telehealth
Dietary Supplement · Other · Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Whole Body Periodic Acceleration on Blood Lactate and Recovery

NCT02482597
View directory record Official record
Conditions
Acidosis, Lactic
Interventions
Whole Body Periodic Acceleration
Device
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

NCT06634797
View directory record Official record
Conditions
Healthy Volunteers
Interventions
mRNA-1273.712, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
12 Years to 30 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
24
States / cities
Phoenix, Arizona • Huntington Park, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Birth to Three - Cavity Free

NCT05756413
View directory record Official record
Conditions
Caries,Dental
Interventions
Self-determination theory
Behavioral
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 45 Years
Enrollment
1,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
16
States / cities
Anamosa, Iowa • Belle Plaine, Iowa • Cedar Rapids, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Comparison of Two School Based Interventions to Manage Anxiety in Autistic Students

NCT05863520
View directory record Official record
Conditions
Autism Spectrum Disorder, Anxiety Disorders, Emotion Regulation
Interventions
Zones of Regulation, Facing Your Fears - School Based
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 15 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 1 Interventional

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

NCT05187182
View directory record Official record
Conditions
Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
Interventions
CA-4948, Nivolumab, Pembrolizumab, Trastuzumab, mFOLFOX7
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer

NCT01274624
View directory record Official record
Conditions
KRAS Mutant Metastatic Colorectal Cancer
Interventions
REOLYSIN®, Irinotecan, Leucovorin, Fluorouracil (5-FU), Bevacizumab
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Early Phase 1 Interventional Results available

Aspirin Resistance in Coronary Artery Disease

NCT00753935
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
enteric-coated aspirin, Chewable aspirin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
40 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Not yet recruiting Phase 1 Interventional

Topical TOR-582 Treatment of Epistaxis in HHT

NCT07667413
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis
Interventions
Topical sirolimus ointment
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 1 Interventional

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

NCT05366179
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
CAR.B7-H3T cells infusion
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 4 Interventional

Naltrexone in AUD Reward Drinkers

NCT05028062
View directory record Official record
Conditions
Alcohol Use Disorder, Alcoholism
Interventions
XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS

NCT02351635
View directory record Official record
Conditions
Inflammatory Bowel Disease, Irritable Bowel Syndrome
Interventions
fecal calprotectin level
Other
Lead sponsor
Bühlmann Laboratories AG
Industry
Eligibility
22 Years and older
Enrollment
478 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Miami, Florida • Macon, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT03606174
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
36
States / cities
Tucson, Arizona • Irvine, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00105443
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional

Intergenerational Transmission of Traumatic Stress

NCT05264415
View directory record Official record
Conditions
Stress, Psychological, Stress Disorders, Traumatic, Emotion Regulation, Behavior, Child, Emotional Stress, Trauma, Psychological, Anxiety, Depression, Coping Skills, Parent-Child Relations, Parenting
Interventions
Families OverComing Under Stress (FOCUS) for Early Childhood (FOCUS-EC), Parenting Education Website
Behavioral · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
3 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Phase 1 Interventional

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

NCT05401110
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Lung Cancer
Interventions
Osimertinib, Carotuximab
Drug
Lead sponsor
Karen Reckamp, MD, MS
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Beverly Hills, California • Los Angeles, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

NCT04670068
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
CAR.B7-H3, Fludarabine, Cyclophosphamide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 5:25 AM EDT